Psychoneuroendocrinology
Volume 35, Issue 8 , Pages 1142-1147 , September 2010

Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia

  • Jayashri Kulkarni

      Affiliations

    • Monash Alfred Psychiatry Research Centre, The Alfred and Monash University School of Psychology, Psychiatry and Psychological Medicine, Melbourne, Australia
    • Corresponding Author InformationCorresponding author at: Monash Alfred Psychiatry Research Centre, Level One, Old Baker Building, The Alfred Hospital, Commercial Rd, Melbourne 3004, Victoria, Australia. Tel.: +61 3 9076 6924; fax: +61 3 9076 8545.
  • ,
  • Caroline Gurvich

      Affiliations

    • Monash Alfred Psychiatry Research Centre, The Alfred and Monash University School of Psychology, Psychiatry and Psychological Medicine, Melbourne, Australia
  • ,
  • Stuart J. Lee

      Affiliations

    • Monash Alfred Psychiatry Research Centre, The Alfred and Monash University School of Psychology, Psychiatry and Psychological Medicine, Melbourne, Australia
  • ,
  • Heather Gilbert

      Affiliations

    • Monash Alfred Psychiatry Research Centre, The Alfred and Monash University School of Psychology, Psychiatry and Psychological Medicine, Melbourne, Australia
  • ,
  • Emmy Gavrilidis

      Affiliations

    • Monash Alfred Psychiatry Research Centre, The Alfred and Monash University School of Psychology, Psychiatry and Psychological Medicine, Melbourne, Australia
  • ,
  • Anthony de Castella

      Affiliations

    • Monash Alfred Psychiatry Research Centre, The Alfred and Monash University School of Psychology, Psychiatry and Psychological Medicine, Melbourne, Australia
  • ,
  • Michael Berk

      Affiliations

    • Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Geelong, Australia
    • Orygen Research Centre, Parkville, Australia
    • Mental Health Research Institute of Victoria, Parkville, Australia
  • ,
  • Seetal Dodd

      Affiliations

    • Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Geelong, Australia
  • ,
  • Paul B. Fitzgerald

      Affiliations

    • Monash Alfred Psychiatry Research Centre, The Alfred and Monash University School of Psychology, Psychiatry and Psychological Medicine, Melbourne, Australia
  • ,
  • Susan R. Davis

      Affiliations

    • Women's Health Program, Department of Medicine, Monash University, Australia

Received 7 December 2009 ,Revised 15 January 2010 ,Accepted 26 January 2010.

References 

  1. Akhondzadeh S, Nejatisafa AA, Amini H, Mohammadi MR, Larijani B, Kashani L, et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2003;27:1007–1012
  2. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N. Engl. J. Med. 2009;360:573–587
  3. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997;337:1641–1647
  4. DonCarlos LL, Azcoitia I, Garcia-Segura LM. Neuroprotective actions of selective estrogen receptor modulators. Psychoneuroendocrinology. 2009;34:S113–S122
  5. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637–645
  6. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology. 2003;28:17–54
  7. Häfner H, Behrens S, De Vry J, Gattaz WF. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatry Res. 1991;38:125–134
  8. Huang Y, Huang YL, Lai B, Zheng P, Zhu YC, Yao T. Raloxifene acutely reduces glutamate-induced intracellular calcium increase in cultured rat cortical neurons via inhibition of high-voltage-activated calcium current. Neuroscience. 2007;147:334–341
  9. Kulkarni J, de Castella A, Fitzgerald PB, Gurvich CT, Bailey M, Bartholomeusz C, et al. Estrogen in severe mental illness: a potential new treatment approach. Arch. Gen. Psychiatry. 2008;65:955–960
  10. Kulkarni J, Gurvich C, Gilbert H, Mehmedbegovic F, Mu L, Marston N, et al. Hormone modulation: a novel therapeutic approach for women with severe mental illness. Aust. N. Z. J. Psychiatry. 2008;42:83–88
  11. Littleton-Kearney MT, Ostrowski NL, Cox DA, Rossberg MI, Hurn PD. Selective estrogen receptor modulators: tissue actions and potential for CNS protection. CNS Drug Rev. 2002;8:309–330
  12. Meaney AM, O’Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr. Res. 2007;93:136–143
  13. Moses EL, Drevets WC, Smith G, Mathis CA, Kalro BN, Butters MA, et al. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol. Psychiatry. 2000;48:854–860
  14. Williams LJ, Henry MJ, Berk M, Dodd S, Jacka FN, Kotowicz MA, et al. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int. Clin. Psychopharmacol. 2008;23:84–87
  15. Wong J, Seeman MV, Shapiro H. Case report: raloxifene in postmenopausal women with psychosis: preliminary findings. Am. J. Geriatr. Psychiatry. 2003;11:697
  16. Yaffe K, Krueger K, Cummings SR, Blackwell T, Henderson VW, Sarkar S, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am. J. Psychiatry. 2005;162:683–690

PII: S0306-4530(10)00030-2

doi: 10.1016/j.psyneuen.2010.01.014

Psychoneuroendocrinology
Volume 35, Issue 8 , Pages 1142-1147 , September 2010